Russian Pharmaceutical Industry Leader
29.10.2021
Pharmasyntez output increased 27%
Pharmasyntez output increased 27%
RNC Pharma published data on changes in drug production in Russia for three quarters of 2021.

The maximum contribution to the company's growth was made by:

  • Bactoflox (INN: Levofloxacin), a levofloxacin infusion form, with a 3.9-fold growth; 

  • Two hypoglycemic drug products: Golda MV (INN: Gliclazide) and Merifatin (INN: Metformin) with a 2.7- and 2.6-fold growth, respectively.


Drug production volume in the Russian Federation for the current year in monetary terms increased by 20% compared to the same indicators of the previous year and amounted to RUB 432.7 billion.

It was also reported that, in comparison with 2020, the pharmaceutical industry in Russia had changed its direction to the production of drugs that are more expensive. The share of drugs with a price over RUB 500 rose by 2.1% and amounted to 49.1% in June. The share of the “below RUB 50” cheap drugs group decreased by 0.9% compared to June of the past year, and was equal to 2.9%.